ArticleJournal of thoracic disease2025
Effect of OK-432 pleurodesis on long-term survival outcomes after pulmonary lobectomy for lung cancer patients: a retrospective case-control study.
Article in Journal of thoracic disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: OK-432 (Picibanil), derived from Methods: This retrospective study analyzed data from 413 patients who underwent pulmonary lobectomy for non-small cell lung cancer between January 2010 and December 2016. Patients were categorized into two groups: those who underwent OK-432 pleurodesis for prolonged air leaks or chylothorax (n=23) and a control group receiving other treatments or none (n=390). We examined demographics, surgical outcomes, and postoperative complications, assessing survival and recurrence using the Kaplan-Meier method and Cox proportional hazards models. Results: The administration of OK-432 effectively managed air leaks and chylothorax without significant complications. There were no statistically significant differences in overall survival (OS), lung cancer-specific survival (LCSS), or recurrence-free survival (RFS) between the groups. Advanced pathological stages were significant predictors of mortality and recurrence. Conclusions: While OK-432 pleurodesis is effective for the management of air leaks and chylothorax following pulmonary lobectomy, this study did not demonstrate any impact on OS, LCSS, or RFS. These findings confirm the utility of OK-432 in addressing immediate postoperative challenges but do not support its use as a prognostic factor in the long-term management of lung cancer. Further investigation is necessary to explore the full spectrum of OK-432's biological effects and potential benefits in a broader oncological context.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.